Valuation: Magenta Therapeutics

Capitalization 42.24M 36.39M 33.91M 31.55M 58.69M 3.82B 62.96M 390M 153M 1.82B 158M 155M 6.69B P/E ratio 2021
-3.42x
P/E ratio 2022 -0.31x
Enterprise value -39.84M -34.31M -31.98M -29.75M -55.35M -3.6B -59.37M -367M -145M -1.72B -149M -146M -6.31B EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
-
Yield 2021 *
-
Yield 2022 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.95%
Current month+293.08%
Current year+293.08%
More quotes
3 years 5.89
Extreme 5.888
46.54
5 years 5.14
Extreme 5.136
227.2
10 years 5.14
Extreme 5.136
336
More quotes

Financials

2021 2022
Net sales - -
Net income -71.14M -61.28M -57.11M -53.13M -98.83M -6.43B -106M -656M -258M -3.07B -267M -261M -11.27B -76.46M -65.86M -61.38M -57.1M -106M -6.91B -114M -705M -278M -3.3B -287M -281M -12.12B
Net Debt -177M -152M -142M -132M -246M -15.99B -264M -1.63B -642M -7.64B -663M -650M -28.04B -82.08M -70.7M -65.89M -61.3M -114M -7.42B -122M -757M -298M -3.55B -308M -301M -13.01B
More financial data * Estimated data
Logo Magenta Therapeutics
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Employees
67
Sector
-
More about the company
Date Price Change Volume
26-01-15 44.00 $ -4.95% 870,135
26-01-14 46.29 $ +3.19% 1,241,739
26-01-13 44.86 $ +14.67% 1,685,190
26-01-12 39.12 $ +2.44% 704,181
26-01-09 38.19 $ +0.18% 920,398

Delayed Quote Nasdaq, January 15, 2026 at 04:00 pm EST

More quotes